FORM PTO-1390 (Modified) (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		**DEX-0154**
		US APPLICATION NO (IF KNOWN, SEE 37 CFR **09/762027**

INTERNATIONAL APPLICATION NO. **PCT/US99/16811**	INTERNATIONAL FILING DATE **22 July 1999**	PRIORITY DATE CLAIMED **4 August 1998**

TITLE OF INVENTION

A Novel Menthod of Diagnosing, Monitoring, Staging, Imaging and Treating Breast Cancer

APPLICANT(S) FOR DO/EO/US

SUN, Yongming et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.

2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))

    a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).

    b. ☐ has been transmitted by the International Bureau.

    c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).

6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).

7. ☒ A copy of the International Search Report (PCT/ISA/210).

8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))

    a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).

    b. ☐ have been transmitted by the International Bureau.

    c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.

    d. ☒ have not been made and will not be made.

9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).

10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). **– Unexecuted**

11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).

12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

15. ☐ A **FIRST** preliminary amendment.

16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.

17. ☐ A substitute specification.

18. ☐ A change of power of attorney and/or address letter.

19. ☐ Certificate of Mailing by Express Mail

20. ☒ Other items or information:

    1) **Courtesy copy of International Application**
    2) **Executed Verified Statement Claiming Small Entity Status**
    3) **Written Opinion**
    4) **Return Post Card**

"Express Mail" Label No. **EL722986085US**
Date of Deposit **February 1, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10. on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By _Deborah Ehret_
Typed Name: Deborah Ehret

PCTUS1/REV03

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR **09/762027**	INTERNATIONAL APPLICATION NO. **PCT/US99/16811**	ATTORNEY'S DOCKET NUMBER **DEX-0154**

21.   The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO $1,000.00		
☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but Internation Search Report prepared by the EPO or JPO $860.00		
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO $710.00		
☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) $690.00		
☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) $100.00		

ENTER APPROPRIATE BASIC FEE AMOUNT =	$860.00	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	$0.00	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	14 - 20 =	0	x $18.00	$0.00	
Independent claims	7 - 3 =	4	x $80.00	$320.00	
Multiple Dependent Claims **(check if applicable).**			☐	$0.00	

TOTAL OF ABOVE CALCULATIONS =	$1,180.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) **(check if applicable).** ☒	$590.00	
SUBTOTAL =	$590.00	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +	$0.00	
TOTAL NATIONAL FEE =	$590.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐	$0.00	
TOTAL FEES ENCLOSED =	$590.00	

Amount to be: refunded	$
charged	$

☐   A check in the amount of   to cover the above fees is enclosed.

X Credit Card Payment form for $590.00 for filing fee

☐   Please charge my Deposit Account No.   in the amount of   to cover the above fees.

A duplicate copy of this sheet is enclosed.

☒   The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment

to Deposit Account No.   **50-1619**   A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata , Reg. No. 32,257
Kathleen A. Tyrrell, Reg. No. 38,350

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08055
Telephone: (856) 810-1515
Facsimile : (856) 810-1454

SIGNATURE

TYRRELL, Kathleen A.

NAME

38,350

REGISTRATION NUMBER

**1 February 2001**

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:   **DEX-0154**

Inventors: **Sun et al.**

Serial No.:   **09/762,027**

Filing Date: **February 1, 2001**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

Title: **A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Breast Cancer**

I, **Kathleen A. Tyrrell**, Registration No. **38,350**, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: **August 6, 2001,**

Kathleen A. Tyrrell / Registration No. **38,350**

Assistant Commissioner for
   Patents
Washington, D.C. 20231

Dear Sir:

NOTIFICATION OF A CHANGE IN STATUS

Applicant hereby provides notification that the status

of the above-identified application is changed from Small Entity to

Large Entity.

Respectfully submitted,

Kathleen A. Tyrrell
Registration No. 38,350

Date: **August 6, 2001**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Box SEQ

Attorney Docket No.:   DEX-0154

Inventors: **Sun et al.**

Serial No.:   **09/762,027**

Filing Date: **February 1, 2001**

Examiner: **Not yet assigned.**

Group Art Unit: **Not yet assigned.**

Title: **A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Breast Cancer**

I, **Kathleen A. Tyrrell**, Registration No. 38,350, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On this date: <u>**April 26, 2001**</u>

Kathleen A. Tyrrell
Kathleen A. Tyrrell, Registration No. 38,350

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE

In response to the "Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" which was dated **March 29, 2001**, a response to which is due **April 29, 2001**, enclosed herewith is:

( ) Amendment under 1.825;

(XX) Statement to Support Filing and Submission in Accordance with 37 CFR §§1.821 through 1.825;

( ) Substitute pages of the Sequence Listing;

(XX) Substitute copy of the computer readable form of amended Sequence Listing;

(XX) Copy of Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

( ) Petition for Three (3) Month Extension of Time;

( ) Other: _____ .

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,

Kathleen A. Tyrrell
Registration No. 38,350

Date: **April 26, 2001**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Re-run

PCT

RAW SEQUENCE LISTING   DATE: 05/08/2002
PATENT APPLICATION: US/09/762,027   TIME: 10:46:52

Input Set : N:\paola\US09762027.raw
Output Set: N:\CRF3\05082002\I762027.raw

ENTERED

```
 1 <110> APPLICANT: Salceda, Susana
 2        Sun, Yongming
 3        Recipon, Herve
 4        DIADEXUS LLC
 5 <120> TITLE OF INVENTION: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING ,
 6        IMAGING AND TREATING BREAST CANCER
 7 <130> FILE REFERENCE: DEX-0040
 8 <140> CURRENT APPLICATION NUMBER: US/09/762,027
 9 <141> CURRENT FILING DATE: 2001-02-01
10 <150> PRIOR APPLICATION NUMBER: 60/095,232
11 <151> PRIOR FILING DATE: 1998-08-04
12 <160> NUMBER OF SEQ ID NOS: 9
13 <170> SOFTWARE: PatentIn Ver. 2.0
15 <210> SEQ ID NO: 1
16 <211> LENGTH: 544
17 <212> TYPE: DNA
18 <213> ORGANISM: Homo sapiens
19 <220> FEATURE:
20 <221> NAME/KEY: unsure
21 <222> LOCATION: (505)..(506)
22 <221> NAME/KEY: unsure
23 <222> LOCATION: (510)
W--> 24 <221> unsure
25 <222> LOCATION: (521)
W--> 26 <221> unsure
27 <222> LOCATION: (527)..(528)
W--> 28 <221> unsure
29 <222> LOCATION: (531)
W--> 30 <221> unsure
31 <222> LOCATION: (534)..(535)
W--> 32 <221> unsure
33 <222> LOCATION: (540)..(541)
W--> 34 <400> 1
35        ctagtctcga gtctagagcg ccttgccttc tcttaggctt tgaagcattt ttgtctgtgc 60
36        tccctgatct tcatgtcacc accatgaagt tcttagcagt cctggtactc ttgggagttt 120
37        ccatctttct ggtctctgcc cagaatccga caacagctgc tccagctgac acgtatccag 180
38        ctactggtcc tgctgatgat gaagcccctg atgctgaaac cactgctgct gcaaccactg 240
39        cgaccactgc tgctcctacc actgcaacca ccgctgcttc taccactgct cgtaaagaca 300
40        ttccagtttt acccaaatgg gttggggatc tcccgaatgg tagagtgtgt ccctgagatg 360
41        gaatcagctt gagtcttctg caattggtca caactattca tgcttcctgt gatttcatcc 420
42        aactacttac cttgcctacg atatcccctt tatctctaat cagtttattt tctttcaaat 480
W--> 43        aaaaaataac tatgagcaac taaannaaan aaaaaaaaaa naaaaannaa naannaaaan 540
W--> 44        naga 544
```

RAW SEQUENCE LISTING   DATE: 05/08/2002
PATENT APPLICATION: US/09/762,027   TIME: 10:46:52

Input Set : N:\paola\US09762027.raw
Output Set: N:\CRF3\05082002\I762027.raw

```
46 <210> SEQ ID NO: 2
47 <211> LENGTH: 1066
48 <212> TYPE: DNA
49 <213> ORGANISM: Homo sapiens
50 <220> FEATURE:
51 <221> NAME/KEY: unsure
52 <222> LOCATION: (729)..(813)
53 <400> SEQUENCE: 2
54     gttgaccagt ggtcatgcca ctgcctgttg atttgttgaa aatattgttt acacgtatgt 60
55     tcttgttact gattgtcaga aagctggttt tgagactgca gcttggacta aattcagtca 120
56     tctggctgtc tggggaagca tgctgaccag tctggtgttc tttggcatct actcagccat 180
57     ctggtccacc attctcattg ccccaaatat gagaggacag aagaatggta ccggtactgc 240
58     caatggagat ggaggaagga gacagaaaga aacagagccc agaccctagg gaccaccagc 300
59     atttgcagaa tggataaaca gccttcttcc taacaaagga agcacagcaa ctgtgatcct 360
60     gagctgtgca cacttctggt tgggattatt tctggtttct acttcctgtt tgaagatgtg 420
61     gcatggagag tgaacaagct gctgcccacc acctggcatc acagccccag aactcagcta 480
62     tttccatggg accacagcat ctcatctctg ggctgagcca gaaagacccc tactgaagtc 540
63     cagaggcact tttctgaaag gctctgcttt gacctgaagt attttatcta tcctcagtct 600
64     caggacactg ttgatggaat taaggccaag cacatctgca aaaagacat tgctggagga 660
65     ggtgcaaaga gctggaaacc aagtctccag tcctgggaaa agcagtggta tggaaaagca 720
66     atggaaagnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780
67     nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnncatagca ccaatgacct gaagagcctt 840
68     gttgaaggaa gactccatct gatgactcag agcaagtatt ttttagtgtg ttattgttat 900
69     tagcagaaag agggccataa aatacatggg gcaagctgaa tatatcttag gcaaaagaag 960
70     aaaatattca aattcttatg ttatttttatc taattatttt atctcttttt gtgtgtgact 1020
71     tataatgtgt gtattgtatt aataaaagta tataaacatg tagttt 1066
73 <210> SEQ ID NO: 3
74 <211> LENGTH: 649
75 <212> TYPE: DNA
76 <213> ORGANISM: Homo sapiens
77 <400> SEQUENCE: 3
78     gcaatgttta atatctcata agctatacac acctcgaagc catcaatgac aacctttct 60
79     tgctgaatag aacagtgatt gatgtcatga agacaatttt atctcctttt gccttccata 120
80     atttgtacca ggttatataa tagtataaca ctgccaagga gcggattatc tcatcttcat 180
81     cctgtaattc cagtgtttgt cacgtggttg ttgaataaat gaataaagaa tgagaaaacc 240
82     agaagctctg atacataatc ataatgataa ttatttcaat gcacaactac gggtggtgct 300
83     gaactagaat ctatattttc tgaaactggc tcctctagga tctactaatg atttaaatct 360
84     aaaagatgaa gttagtaaag catcagaaaa aaaaggtaaa caaattgctc ctgtggagat 420
85     gattggcatc acatggtgtt ttgagctgat acacccaaca cttgagctca ctgcaacagt 480
86     accagatttt caccgctatg cctcctttca ctctgggagt cttccagagg tcttgcactc 540
87     gggagagcat gctcaggttt ccccagctct acaaaatcac ccagaatgcc aaagacttca 600
88     acacaagggt aaataaggtt gatctcagaa ttgtcacctc aaaaaggcc 649
90 <210> SEQ ID NO: 4
91 <211> LENGTH: 388
92 <212> TYPE: DNA
93 <213> ORGANISM: Homo sapiens
94 <220> FEATURE:
95 <221> NAME/KEY: unsure
96 <222> LOCATION: (378)
```

```
     97 <221> NAME/KEY: unsure
     98 <222> LOCATION: (385)
W--> 99 <400> 4
    100      agctgctcaa tacggaacat attctcagtc ctcctctggt ctacaaagcc tgtgatttct 60
    101      tgtctatgga cagaacgtct ggtttaatct acaggaaccc ataacttcct gaagctttat 120
    102      gcttaacagt gacaacgtga gtcagttgaa tttttattgtg tttcagtccg tagagtatta 180
    103      gctaacagaa acctttccat tgccatactg agaaactggc agcaggcagt gtgcctacag 240
    104      gtctacaaag aaacttcaga tcatcttctt gagggaaaga agctgaagtg ctacataaga 300
    105      tgcttgtgct tcataactct cagaagctgc agattctgta taaatcctta gaaaagagca 360
W--> 106      tcccctgaat ccataaangt atatngcg                                    388
    108 <210> SEQ ID NO: 5
    109 <211> LENGTH: 1227
    110 <212> TYPE: DNA
    111 <213> ORGANISM: Homo sapiens
    112 <220> FEATURE:
    113 <221> NAME/KEY: unsure
    114 <222> LOCATION: (327)
    115 <221> NAME/KEY: unsure
    116 <222> LOCATION: (352)
W--> 117 <221> unsure
    118 <222> LOCATION: (369)
W--> 119 <221> unsure
    120 <222> LOCATION: (850)..(880)
W--> 121 <221> unsure
    122 <222> LOCATION: (1220)
W--> 123 <400> 5
    124      attttgtagt tcagcaaatc ctccaaatac acagcatgtt acaaggcact ggtggcacag 60
    125      ggcacaacag gaaatgatat ttatttagca aattcattta acaaatatta ttgggcacct 120
    126      gttatgtgag acactgtcct aggcactgtg ggataacaac agcaaacact tcacacaaca 180
    127      gcctggcctt cctgtgtttt acaacagctc ctaaagatag ctgatatcaa gacatttgag 240
    128      ggacacagtt catgtagaat caaaatatta gtatttcaga ataaggattt ttttttctgaa 300
W--> 129      aagcatacag agaggaaaca gcttaanaat aggtcaagac ctaaaaacag antataatca 360
W--> 130      cggaataanc tggataaccc agacagtccc cacagaattt ctttcaggtc acagatttct 420
    131      taaaactcac ccccaaaatg tgcctgcttg gttgtttgaa tcttgcataa ttaatgtcac 480
    132      aggcgcaagc cgctgaactt agttgagatg cagaaaacaa acaaatgcaa tgacatatct 540
    133      gagaagcatt tatgtaactc cggttaagtg gtgaggaggg gtgtgtgaag acagtgtgca 600
    134      tgcatgagtg tgtattcata tatatgtgta tacatatgaa tttcactgtt attttccagg 660
    135      gtctatggac aatgtggcag taagagtcta tgatgttctg aaacttttca cagtaaatcc 720
    136      aaagattaca gaccttacaa ggtgcttgca ttctgttgct tttccatctg tcacttctca 780
    137      ggttatttga ctgtgttcaa accttctttt ctttttcatt gagtttcatt ttttaagctt 840
W--> 138      gttaaatgcn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn tgtcattttt cacattatcc 900
    139      tctcttctct gcaacaagga tagtaagatg tagatgaatg caaaaataat aacaacaata 960
    140      aggaaatata ttaaagcttt aaaatatgca catatgtagt tctaaagagc aataacggta 1020
    141      gtatctattt cgaacatgca ttaggcaaaa aagaaatcaa aactgaaatt ttcgtgtatt 1080
    142      tttcccttg taagatgttc aaatgctaac ttcattttct cctttcctct atgtggcact 1140
    143      ttctcaaaat atctatgaaa tactttagaa caaagattga gctggagaaa gagatacaaa 1200
W--> 144      tttccatccc cccagacagn gagacat                                     1227
    146 <210> SEQ ID NO: 6
    147 <211> LENGTH: 253
```

```
      148 <212> TYPE: DNA
      149 <213> ORGANISM: Homo sapiens
      150 <220> FEATURE:
      151 <221> NAME/KEY: unsure
      152 <222> LOCATION: (181)
      153 <221> NAME/KEY: unsure
      154 <222> LOCATION: (201)
W--> 155 <221> unsure
      156 <222> LOCATION: (205)
W--> 157 <221> unsure
      158 <222> LOCATION: (238)
W--> 159 <221> unsure
      160 <222> LOCATION: (241)..(242)
W--> 161 <221> unsure
      162 <222> LOCATION: (250)
W--> 163 <400> 6
      164       gaacagcctc acttgtgttg ctgtcagtgc cagtagggca ggcaggaatg cagcagagag 60
      165       gactcgccat cgtggccttg gctgtctgtg cggccctaca tgcctcagaa gccatacttc 120
      166       ccattgcctc cagctgttgc acggaggttt cacatcatat ttccagaagg ctcctggaaa 180
W--> 167       nagtgaatat gtgtcgcatc naganagctg atggggattg tgacttggct gctgtcancc 240
W--> 168       nncatgtcan gcg                                                     253
      170 <210> SEQ ID NO: 7
      171 <211> LENGTH: 943
      172 <212> TYPE: DNA
      173 <213> ORGANISM: Homo sapiens
      174 <220> FEATURE:
      175 <221> NAME/KEY: unsure
      176 <222> LOCATION: (128)
      177 <221> NAME/KEY: unsure
      178 <222> LOCATION: (130)
W--> 179 <221> unsure
      180 <222> LOCATION: (925)
W--> 181 <400> 7
      182       gggggcctgg ccccggcccc tgtgaggacc ccgcgggtgc tggggtaaga ggctctagac 60
      183       ccttcacctg tcagtcacct gagggaggct gaggccaagc cccatccctc agaatcaagg 120
W--> 184       cttgcaancn cccctcacct gcccagtctc tgtccacacc cctcgggctg aagacggccc 180
      185       tgaccaggcc ctgggcctca gcgaccaccc ctcccctcc tgcctggacc caggagcag 240
      186       gtgcagggg ctccgagccc ctggtgactg tcaccgtgca gtgcgccttc acagtggccc 300
      187       tgagggcacg aagaggagcc gacctgtcca gcctgcgggc actgctgggc caagccctcc 360
      188       ctcaccaggc ccagcttggg caactcaggt gggccagaaa gcccccggtg gctgcggtgg 420
      189       agctgggcac cgccccgact gaggcagctg ctggaagagg gggtggcaga ggtcactgcc 480
      190       ctccctgcag gccccaccca ggaggccccc tctgaggaat ctctttgcag ttacctagcc 540
      191       ccaggtgagg acgggcactg ggtccccatc cccgaggagg agtcgctgca gagggcctgg 600
      192       caggacgcag ctgcctgccc caggggctg cagctgcagt gcaggggagc cggggtcgg 660
      193       ccggtcctct accaggtggt ggcccagcac agctactccg cccaggggcc agaggacctg 720
      194       ggcttccgac aggggacac ggtggacgtc ctgtgtgaag tggaccaggc atggctggag 780
      195       ggccactgtg acggccgcat cggcatcttc cccaagtgct tcgtggtccc cgccggccct 840
      196       cggatgtcag gagcccccgg ccgcctgccc cgatcccagc agggagatca gccctaatga 900
W--> 197       tgctgtgtcc atgatgcttt taatnaaaaa aaccccccact gca                   943
```

```
     199 <210> SEQ ID NO: 8
     200 <211> LENGTH: 249
     201 <212> TYPE: DNA
     202 <213> ORGANISM: Homo sapiens
     203 <220> FEATURE:
     204 <221> NAME/KEY: unsure
     205 <222> LOCATION: (48)
     206 <221> NAME/KEY: unsure
     207 <222> LOCATION: (110)
W--> 208 <221> unsure
     209 <222> LOCATION: (192)
W--> 210 <221> unsure
     211 <222> LOCATION: (205)
W--> 212 <221> unsure
     213 <222> LOCATION: (218)
W--> 214 <400> 8
W--> 215     atcacattaa gtcattgcta attttataaa caaaaacaat ggtttttantt tgcatctccc 60
W--> 216     tgattggtat tgctgtagaa catatttgga gaagtttgtt tgtctttggn gtttatttca 120
     217     tgaatagatt gtgtgcccat tttctcttgg ggtattcagt tttttattac tgatgtgagc 180
W--> 218     atgtgtatgg gngattattt gatgnttatc agttttgntt agtagactgg caatatttag 240
     219     tcttgctgt                                                        249
     221 <210> SEQ ID NO: 9
     222 <211> LENGTH: 690
     223 <212> TYPE: DNA
     224 <213> ORGANISM: Homo sapiens
     225 <400> SEQUENCE: 9
     226     gacgcccagt gacctgccga ggtcggcagc acagagctct ggagatgaag accctgttcc 60
     227     tgggtgtcac gctcggcctg gccgctgccc tgtccttcac cctggaggag gaggatatca 120
     228     cagggacctg gtacgtgaag gccatggtgg tcgataagga ctttccggag gacaggaggc 180
     229     ccaggaaggt gtccccagtg aaggtgacag ccctgggcgg tgggaagttg gaagccacgt 240
     230     tcaccttcat gagggaggat cggtgcatcc agaagaaaat cctgatgcgg aagacggagg 300
     231     agcctggcaa atacagcgcc tatggggca ggaagctcat gtacctgcag gagctgccca 360
     232     ggagggacca ctacatcttt tactgcaaag accagcacca tggggggcctg ctccacatgg 420
     233     gaaagcttgt gggtaggaat tctgatacca accgggaggc cctggaagaa tttaagaaat 480
     234     tggtgcagcg caagggactc tcggaggagg acattttcac gcccctgcag acgggaagct 540
     235     gcgttcccga acactaggca gcccccgggt ctgcacctcc agagcccacc ctaccaccag 600
     236     acacagagcc cggaccacct ggacctaccc tccagccatg acccttccct gctcccaccc 660
     237     acctgactcc aaataaagtc cttctccccc                                  690
```

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 05/08/2002
PATENT APPLICATION: US/09/762,027 TIME: 10:46:53

Input Set : N:\paola\US09762027.raw
Output Set: N:\CRF3\05082002\I762027.raw

Please Note:
Use of n and/or Xaa have been detected in the Sequence Listing. Please review the
Sequence Listing to ensure that a corresponding explanation is presented in the <220>
to <223> fields of each sequence which presents at least one n or Xaa.

```
Seq#:1; N Pos. 505,506,510,521,527,528,531,534,535,540,541
Seq#:2; N Pos. 729,730,731,732,733,734,735,736,737,738,739,740,741,742,743
Seq#:2; N Pos. 744,745,746,747,748,749,750,751,752,753,754,755,756,757,758
Seq#:2; N Pos. 759,760,761,762,763,764,765,766,767,768,769,770,771,772,773
Seq#:2; N Pos. 774,775,776,777,778,779,780,781,782,783,784,785,786,787,788
Seq#:2; N Pos. 789,790,791,792,793,794,795,796,797,798,799,800,801,802,803
Seq#:2; N Pos. 804,805,806,807,808,809,810,811,812,813
Seq#:4; N Pos. 378,385
Seq#:5; N Pos. 327,352,369,850,851,852,853,854,855,856,857,858,859,860,861
Seq#:5; N Pos. 862,863,864,865,866,867,868,869,870,871,872,873,874,875,876
Seq#:5; N Pos. 877,878,879,880,1220
Seq#:6; N Pos. 181,201,205,238,241,242,250
Seq#:7; N Pos. 128,130,925
Seq#:8; N Pos. 48,110,192,205,218
```

```
L:24 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:26 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:28 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:30 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:32 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:34 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:1
L:43 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:1
L:43 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:480
L:44 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:1
L:44 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:540
L:66 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:2
L:66 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:720
L:67 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:2
L:67 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:780
L:92 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:4
L:106 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:4
L:106 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:360
L:117 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:5
L:119 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:5
L:121 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:5
L:123 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:5
L:129 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:5
L:129 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:300
L:130 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:5
L:130 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:360
L:138 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:5
L:138 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:840
L:144 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:5
L:144 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:1200
L:155 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:6
L:157 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:6
L:159 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:6
L:161 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:6
L:163 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:6
L:167 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:6
L:167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:180
L:168 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:6
L:168 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:240
L:179 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:7
L:181 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:7
L:184 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:7
L:184 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:120
L:197 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:7
L:197 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:900
L:208 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:8
L:210 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:8
L:212 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:8
L:214 M:258 W: Mandatory Feature missing, <220> not found for SEQ ID#:8
```

```
L:215 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:8
L:215 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:216 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:8
L:216 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:60
L:218 M:258 W: Mandatory Feature missing, <223> not found for SEQ ID#:8
L:218 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:180
```

SEQUENCE LISTING

<110> Sun, Yongming
      Recipon, Herve
      Cafferkey, Robert
      DIADEXUS LLC

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING ,
      IMAGING AND TREATING BREAST CANCER

<130> DEX-0040

<140>
<141>

<150> 60/095,232
<151> 1998-08-04

<160> 9

<170> PatentIn Ver. 2.0

<210> 1
<211> 544
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (505)..(506)

<220>
<221> unsure
<222> (510)

<220>
<221> unsure
<222> (521)

<220>
<221> unsure
<222> (527)..(528)

<220>
<221> unsure
<222> (531)

<220>

```
<221> unsure
<222> (534)..(535)

<220>
<221> unsure
<222> (540)..(541)


<400> 1
ctagtctcga gtctagagcg ccttgccttc tcttaggctt tgaagcattt ttgtctgtgc 60
tccctgatct tcatgtcacc accatgaagt tcttagcagt cctggtactc ttgggagttt 120
ccatctttct ggtctctgcc cagaatccga caacagctgc tccagctgac acgtatccag 180
ctactggtcc tgctgatgat gaagcccctg atgctgaaac cactgctgct gcaaccactg 240
cgaccactgc tgctcctacc actgcaacca ccgctgcttc taccactgct cgtaaagaca 300
ttccagtttt acccaaatgg gttggggatc tcccgaatgg tagagtgtgt ccctgagatg 360
gaatcagctt gagtcttctg caattggtca caactattca tgcttcctgt gatttcatcc 420
aactacttac cttgcctacg atatcccctt tatctctaat cagtttattt tctttcaaat 480
aaaaaataac tatgagcaac taaannaaan aaaaaaaaaa naaaannaa naannaaaan 540
naga                                                              544


<210> 2
<211> 1066
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (729)..(813)

<400> 2
gttgaccagt ggtcatgcca ctgcctgttg atttgttgaa aatattgttt acacgtatgt 60
tcttgttact gattgtcaga aagctggttt tgagactgca gcttggacta aattcagtca 120
tctggctgtc tggggaagca tgctgaccag tctggtgttc tttggcatct actcagccat 180
ctggtccacc attctcattg ccccaaatat gagaggacag aagaatggta ccggtactgc 240
caatggagat ggaggaagga gacagaaaga aacagagccc agaccctagg gaccaccagc 300
atttgcagaa tggataaaca gccttcttcc taacaaagga agcacagcaa ctgtgatcct 360
gagctgtgca cacttctggt tgggattatt tctggtttct acttcctgtt tgaagatgtg 420
gcatggagag tgaacaagct gctgcccacc acctggcatc acagccccag aactcagcta 480
tttccatggg accacagcat ctcatctctg ggctgagcca gaaagacccc tactgaagtc 540
cagaggcact tttctgaaag gctctgcttt gacctgaagt attttatcta tcctcagtct 600
caggacactg ttgatggaat taaggccaag cacatctgca aaaagacat tgctggagga 660
ggtgcaaaga gctggaaacc aagtctccag tcctgggaaa agcagtggta tggaaaagca 720
atggaaagnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnncatagca ccaatgacct gaagagcctt 840
gttgaaggaa gactccatct gatgactcag agcaagtatt ttttagtgtg ttattgttat 900
tagcagaaag agggccataa aatacatggg gcaagctgaa tatatcttag gcaaaagaag 960
aaaatattca aattcttatg ttattttatc taattatttt atctcttttt gtgtgtgact 1020
tataatgtgt gtattgtatt aataaaagta tataaacatg tagttt 1066
```

```
<210> 3
<211> 649
<212> DNA
<213> Homo sapiens

<400> 3
gcaatgttta atatctcata agctatacac acctcgaagc catcaatgac aacctttтct    60
tgctgaatag aacagtgatt gatgtcatga agacaatttt atctcctttt gccttccata   120
atttgtacca ggttatataa tagtataaca ctgccaagga gcggattatc tcatcttcat   180
cctgtaattc cagtgtttgt cacgtggttg ttgaataaat gaataaagaa tgagaaaacc   240
agaagctctg atacataatc ataatgataa ttatttcaat gcacaactac gggtggtgct   300
gaactagaat ctatattttc tgaaactggc tcctctagga tctactaatg atttaaatct   360
aaaagatgaa gttagtaaag catcagaaaa aaaaggtaaa caaattgctc ctgtggagat   420
gattggcatc acatggtgtt ttgagctgat acacccaaca cttgagctca ctgcaacagt   480
accagatttt caccgctatg cctcctttca ctctgggagt cttccagagg tcttgcactc   540
gggagagcat gctcaggttt ccccagctct acaaaatcac ccagaatgcc aaagacttca   600
acacaagggt aaataaggtt gatctcagaa ttgtcacctc aaaaaggcc               649

<210> 4
<211> 388
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (378)

<220>
<221> unsure
<222> (385)

<400> 4
agctgctcaa tacggaacat attctcagtc ctcctctggt ctacaaagcc tgtgatttct    60
tgtctatgga cagaacgtct ggtttaatct acaggaaccc ataacttcct gaagctttat   120
gcttaacagt gacaacgtga gtcagttgaa ttttattgtg tttcagtccg tagagtatta   180
gctaacagaa acctttccat tgccatactg agaaactggc agcaggcagt gtgcctacag   240
gtctacaaag aaacttcaga tcatcttctt gagggaaaga agctgaagtg ctacataaga   300
tgcttgtgct tcataactct cagaagctgc agattctgta taaatcctta gaaaagagca   360
tccctgaat ccataaangt atatngcg                                       388

<210> 5
<211> 1227
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (327)
```

```
<220>
<221> unsure
<222> (352)

<220>
<221> unsure
<222> (369)

<220>
<221> unsure
<222> (850)..(880)

<220>
<221> unsure
<222> (1220)

<400> 5
attttgtagt tcagcaaatc ctccaaatac acagcatgtt acaaggcact ggtggcacag 60
ggcacaacag gaaatgatat ttatttagca aattcattta acaaatatta ttgggcacct 120
gttatgtgag acactgtcct aggcactgtg ggataacaac agcaaacact tcacacaaca 180
gcctggcctt cctgtgtttt acaacagctc ctaaagatag ctgatatcaa gacatttgag 240
ggacacagtt catgtagaat caaaatatta gtatttcaga ataaggattt tttttctgaa 300
aagcatacag agaggaaaca gcttaanaat aggtcaagac ctaaaaacag antataatca 360
cggaataanc tggataaccc agacagtccc cacagaattt ctttcaggtc acagatttct 420
taaaactcac ccccaaaatg tgcctgcttg gttgtttgaa tcttgcataa ttaatgtcac 480
aggcgcaagc cgctgaactt agttgagatg cagaaaacaa acaaatgcaa tgacatatct 540
gagaagcatt tatgtaactc cggttaagtg gtgaggaggg gtgtgtgaag acagtgtgca 600
tgcatgagtg tgtattcata tatatgtgta tacatatgaa tttcactgtt attttccagg 660
gtctatggac aatgtggcag taagagtcta tgatgttctg aaacttttca cagtaaatcc 720
aaagattaca gaccttacaa ggtgcttgca ttctgttgct tttccatctg tcacttctca 780
ggttatttga ctgtgttcaa accttctttt ctttttcatt gagtttcatt ttttaagctt 840
gttaaatgcn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn tgtcatttt cacattatcc 900
tctcttctct gcaacaagga tagtaagatg tagatgaatg caaaaataat aacaacaata 960
aggaaatata ttaaagcttt aaaatatgca catatgtagt tctaaagagc aataacggta 1020
gtatctattt cgaacatgca ttaggcaaaa aagaaatcaa aactgaaatt ttcgtgtatt 1080
tttccccttg taagatgttc aaatgctaac ttcattttct cctttcctct atgtggcact 1140
ttctcaaaat atctatgaaa tacttttaga caaagattga gctggagaaa gagatacaaa 1200
tttccatccc cccagacagn gagacat                                     1227

<210> 6
<211> 253
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (181)
```

```
<220>
<221> unsure
<222> (201)


<220>
<221> unsure
<222> (205)


<220>
<221> unsure
<222> (238)


<220>
<221> unsure
<222> (241)..(242)


<220>
<221> unsure
<222> (250)


<400> 6
gaacagcctc acttgtgttg ctgtcagtgc cagtagggca ggcaggaatg cagcagagag 60
gactcgccat cgtggccttg gctgtctgtg cggccctaca tgcctcagaa gccatacttc 120
ccattgcctc cagctgttgc acggaggttt cacatcatat ttccagaagg ctcctggaaa 180
nagtgaatat gtgtcgcatc naganagctg atggggattg tgacttggct gctgtcancc 240
nncatgtcan gcg                                                    253

<210> 7
<211> 943
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (128)


<220>
<221> unsure
<222> (130)


<220>
<221> unsure
<222> (925)


<400> 7
gggggcctgg ccccggcccc tgtgaggacc ccgcgggtgc tggggtaaga ggctctagac 60
ccttcacctg tcagtcacct gagggaggct gaggccaagc cccatccctc agaatcaagg 120
```

5

```
cttgcaancn  cccctcacct  gcccagtctc  tgtccacacc  cctcgggctg  aagacggccc 180
tgaccaggcc  ctgggcctca  gcgaccaccc  ctccccctcc  tgcctggacc  cagggagcag 240
gtgcagggggg ctccgagccc  ctggtgactg  tcaccgtgca  gtgcgccttc  acagtggccc 300
tgagggcacg  aagaggagcc  gacctgtcca  gcctgcgggc  actgctgggc  caagccctcc 360
ctcaccaggc  ccagcttggg  caactcaggt  gggccagaaa  gccccggtg   ctgcggtgg  420
agctgggcac  cgccccgact  gaggcagctg  ctggaagagg  gggtggcaga  ggtcactgcc 480
ctccctgcag  gccccaccca  ggaggccccc  tctgaggaat  ctctttgcag  ttacctagcc 540
ccaggtgagg  acgggcactg  ggtccccatc  cccgaggagg  agtcgctgca  gagggcctgg 600
caggacgcag  ctgcctgccc  cagggggctg  cagctgcagt  gcaggggagc  cgggggtcgg 660
ccggtcctct  accaggtggt  ggcccagcac  agctactccg  cccagggggcc agaggacctg 720
ggcttccgac  agggggacac  ggtggacgtc  ctgtgtgaag  tggaccaggc  atggctggag 780
ggccactgtg  acggccgcat  cggcatcttc  cccaagtgct  tcgtggtccc  cgccggccct 840
cggatgtcag  gagcccccgg  ccgcctgccc  cgatcccagc  agggagatca  gccctaatga 900
tgctgtgtcc  atgatgcttt  taatnaaaaa  aaccccccact gca                    943
```

```
<210> 8
<211> 249
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> (48)

<220>
<221> unsure
<222> (110)

<220>
<221> unsure
<222> (192)

<220>
<221> unsure
<222> (205)

<220>
<221> unsure
<222> (218)

<400> 8
atcacattaa  gtcattgcta  attttataaa  caaaaacaat  ggttttantt  tgcatctccc  60
tgattggtat  tgctgtagaa  catatttgga  gaagtttgtt  tgtctttggn  gtttatttca 120
tgaatagatt  gtgtgcccat  tttctcttgg  ggtattcagt  tttttattac  tgatgtgagc 180
atgtgtatgg  gngattattt  gatgnttatc  agttttgntt  agtagactgg  caatatttag 240
tcttgctgt                                                              249

<210> 9
```

<211> 690

<212> DNA

<213> Homo sapiens

<400> 9

```
gacgcccagt gacctgccga ggtcggcagc acagagctct ggagatgaag accctgttcc 60
tgggtgtcac gctcggcctg gccgctgccc tgtccttcac cctggaggag gaggatatca 120
cagggacctg gtacgtgaag gccatggtgg tcgataagga ctttccggag gacaggaggc 180
ccaggaaggt gtccccagtg aaggtgacag ccctgggcgg tgggaagttg gaagccacgt 240
tcaccttcat gagggaggat cggtgcatcc agaagaaaat cctgatgcgg aagacggagg 300
agcctggcaa atacagcgcc tatggggggca ggaagctcat gtacctgcag gagctgccca 360
ggagggacca ctacatcttt tactgcaaag accagcacca tgggggcctg ctccacatgg 420
gaaagcttgt gggtaggaat tctgatacca accgggaggc cctggaagaa tttaagaaat 480
tggtgcagcg caagggactc tcggaggagg acattttcac gcccctgcag acgggaagct 540
gcgttcccga acactaggca gccccgggt ctgcacctcc agagcccacc ctaccaccag 600
acacagagcc cggaccacct ggacctaccc tccagccatg acccttccct gctcccaccc 660
acctgactcc aaataaagtc cttctcccccc                                  690
```

A NOVEL METHOD OF DIAGNOSING,
MONITORING, STAGING, IMAGING AND TREATING BREAST CANCER

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging,
prognosticating, imaging and treating cancers, particularly
breast cancer.

BACKGROUND OF THE INVENTION

10 One of every nine American women will develop breast
cancer sometime during her life based on a lifespan of 85
years. Annually, over 180,000 women in the United States will
be diagnosed with breast cancer and approximately 46,000 will
die of the disease.

15 Every woman is at risk for breast cancer. A woman's
chances of developing breast cancer increase as she grows
older; 80 percent of all cancers are found in women over the
age of 50. There are also several risk factors that can
increase a woman's chances of developing cancer. A woman may
20 be at increased risk if she has a family history of the
disease, if she had her first child after the age of 30 or has
no children, or if she began menstruating early.

However, more than 70 percent of women who develop
breast cancer have no known risk factors. Less than 10 percent
25 of breast cancer cases are thought to be related to the BRCA1
gene discovered in 1994. Researchers are now investigating
the role other factors such as nutrition, alcohol, exercise,
smoking, and oral contraceptives may play in cancer
prevention.

30 As with many other cancers, the best chance for
successful treatment occurs when breast cancer is found early.

Mammograms, special x-rays of the breast, can detect more than 90 percent of all breast cancers. If breast cancer is found early, the chance of cure is greater than 90 percent. Treatment options include surgery, chemotherapy, and radiation
5 therapy depending on the stage of the cancer.

Procedures used for detecting, diagnosing, monitoring, staging, prognosticating and imaging breast cancer are of critical importance to the outcome of the patient. Patients diagnosed with early breast cancer generally have a much
10 greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized breast cancer. New diagnostic methods which are more sensitive and specific for detecting early breast cancer are clearly needed.

Breast cancer patients are closely monitored following
15 initial therapy and during adjuvant therapy to determine response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a breast cancer marker which is more sensitive and specific in detecting breast cancer and its recurrence and progression.

20 Another important step in managing breast cancer is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of breast cancer is preferable over
25 clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of breast cancer would be
30 improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion.

In the present invention methods are provided for detecting, diagnosing, monitoring, staging, prognosticating,
35 imaging and treating breast cancer via 9 Breast Specific Genes

(BSGs). The 9 BSGs refer, among other things, to native proteins expressed by the genes comprising the polynucleotide sequences of any of SEQ ID NO: 1-9. In the alternative, what is meant by the 9 BSGs as used herein, means the native mRNAs

5   encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1-9 or it can refer to the actual genes comprising any of the polynucleotide sequences of SEQ ID NO: 1-9.

Other objects, features, advantages and aspects of the

10 present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various

15 changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

20   Toward these ends, and others, it is an object of the present invention to provide a method for diagnosing the presence of breast cancer by analyzing for changes in levels of BSG in cells, tissues or bodily fluids compared with levels of BSG in preferably the same cells, tissues, or bodily fluid

25 type of a normal human control, wherein a change in levels of BSG in the patient versus the normal human control is associated with breast cancer.

Further provided is a method of diagnosing metastatic breast cancer in a patient having such cancer which is not

30 known to have metastasized by identifying a human patient suspected of having breast cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for BSG; comparing the BSG levels in such cells, tissues, or bodily fluid with levels of BSG in preferably the

- 4 -

same cells, tissues, or bodily fluid type of a normal human control, wherein a change in BSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5   Also provided by the invention is a method of staging breast cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for BSG; comparing BSG levels in such cells, tissues, or bodily fluid
10   with levels of BSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein a change in BSG levels in the patient versus the normal human control is associated with a cancer which is progressing or regressing or in remission.

15   Further provided is a method of monitoring breast cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from
20   such patient for BSG; comparing the BSG levels in such cells, tissue, or bodily fluid with levels of BSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein a change in BSG levels in the patient versus the normal human control is associated with a cancer
25   which has metastasized.

          Further provided is a method of monitoring the change in stage of breast cancer in a human having such cancer by looking at levels of BSG in a human having such cancer. The method comprises identifying a human patient having such
30   cancer; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for BSG; comparing the BSG levels in such cells, tissue, or bodily fluid with levels of BSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein a change in BSG
35   levels in the patient versus the normal human control is

- 5 -

associated with a cancer which is progressing or regressing or in remission.

Further provided are antibodies against the BSGs or fragments of such antibodies which can be used to detect or
5   image localization of the BSGs in a patient for the purpose of detecting or diagnosing a disease or condition. Such antibodies can be polyclonal or monoclonal, or prepared by molecular biology techniques. The term "antibody", as used herein and throughout the instant specification is also meant
10 to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic
15 metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of a BSG. In therapeutic applications, the antibody can be used without or with derivatization to a cytotoxic agent such as a radioisotope,
20 enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the
25 specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and
30 from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, prognosticating and imaging

- 6 -

cancers by comparing levels of BSG with those of BSG in a
normal human control. What is meant by levels of BSG as used
herein, means levels of the native protein expressed by the
genes comprising the polynucleotide sequence of any of SEQ ID
5   NO: 1-9. In the alternative, what is meant by levels of BSG
as used herein, means levels of the native mRNA encoded by any
of the genes comprising any of the polynucleotide sequences
of SEQ ID NO: 1-9 or levels of the gene comprising any of the
polynucleotide sequence of SEQ ID NO: 1-9. Such levels are
10   preferably measured in at least one of, cells, tissues and/or
bodily fluids, including determination of normal and abnormal
levels. Thus, for instance, a diagnostic assay in accordance
with the invention for measuring changes in levels of any one
of the BSG proteins compared to normal control bodily fluids,
15   cells, or tissue samples may be used to diagnose the presence
of cancers, including breast cancer. By "change" it is meant
either an increase or decrease in levels of the BSG. For
example, for BSGs such as Mam001 (SEQ ID NO:2), Mam004 (SEQ
ID NO:4) and Mam005 (SEQ ID NO:3), an increase in levels as
20   compared to normal human controls is associated with breast
cancer, metastasis and progression of the cancer, while a
decrease in levels is association with regression and/or
remission. For the BSG Mam002 (SEQ ID NO:1), a decrease in
levels as compared to normal human controls is associated with
25   breast cancer, metastasis and progression while an increase
is associated with regression and/or remission. Any of the
9 BSGs may be measured alone in the methods of the invention,
or all together or any combination of the nine.

All the methods of the present invention may optionally
30   include measuring the levels of other cancer markers as well
as BSG. Other cancer markers, in addition to BSG, such as
BRCA1 are known to those of skill in the art.

Diagnostic Assays

The present invention provides methods for diagnosing the presence of breast cancer by analyzing for changes in levels of BSG in cells, tissues or bodily fluids compared with

5   levels of BSG in cells, tissues or bodily fluids of preferably the same type from a normal human control. As demonstrated herein an increase in levels of BSGs such as Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3) in the patient versus the normal human control is associated with the

10 presence of breast cancer, while a decrease in levels of BSGs such as Mam002 (SEQ ID NO:1) in the patient versus the normal human control is associated with the presence of breast cancer.

Without limiting the instant invention, typically, for

15 a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as BSG, are at least two times higher or lower, and most preferably are at least five times higher or lower, than in

20 preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic breast cancer in a patient having breast cancer which has not yet metastasized for the onset of

25 metastasis. In the method of the present invention, a human cancer patient suspected of having breast cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art. For

30 example, in the case of breast cancer, patients are typically diagnosed with breast cancer following traditional detection methods.

In the present invention, determining the presence of BSG level in cells, tissues, or bodily fluid, is particularly

35 useful for discriminating between breast cancer which has not

metastasized and breast cancer which has metastasized. Existing techniques have difficulty discriminating between breast cancer which has metastasized and breast cancer which has not metastasized and proper treatment selection is often

5 dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissues, or bodily fluid is BSG, and are compared with levels of BSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That

10 is, if the cancer marker being observed is just BSG in serum, this level is preferably compared with the level of BSG in serum of a normal human patient. An increase in BSGs such as Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3) in the patient versus the normal human control is

15 associated with breast cancer which has metastasized while a decrease in BSGs such as Mam002 (SEQ ID NO:1) in the patient versus the normal human control is associated with breast cancer which has metastasized.

Without limiting the instant invention, typically, for

20 a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as BSG, are at least two times higher or lower, and most preferably are at least five

25 times higher or lower, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for

30 metastasis, normal human control preferably comprises samples from a human patient that is determined by reliable methods to have breast cancer which has not metastasized, such as earlier samples of the same patient.

Staging

The invention also provides a method of staging breast cancer in a human patient.

The method comprises identifying a human patient having
5 such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for BSG. Then, the method compares BSG levels in such cells, tissues, or bodily fluid with levels of BSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in
10 levels of BSGs such as Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3) or a decrease in levels of BSGs such as Mam002 (SEQ ID NO:1) in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in levels of BSGs such as Mam001 (SEQ ID NO:2),
15 Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3) or an increase in levels of BSGs such as Mam002 (SEQ ID NO:1) is associated with a cancer which is regressing or in remission.

Monitoring

20   Further provided is a method of monitoring breast cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from
25 such patient for BSG; comparing the BSG levels in such cells, tissue, or bodily fluid with levels of BSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in levels of BSGs such as Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID
30 NO:3) or a decrease in levels of BSGs such as Mam002 (SEQ ID NO:1) in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of breast cancer in a human
35 having such cancer. The method comprises identifying a human

patient having such cancer; periodically analyzing a sample
of cells, tissues, or bodily fluid from such patient for BSG;
comparing the BSG levels in such cells, tissue, or bodily
fluid with levels of BSG in preferably the same cells,
5   tissues, or bodily fluid type of a normal human control
sample, wherein an increase in levels of BSGs such as Mam001
(SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3)
or a decrease in levels of BSGs such as Mam002 (SEQ ID NO:1)
in the patient versus the normal human control is associated
10 with a cancer which is progressing in stage and a decrease in
the levels of BSGs such as Mam001 (SEQ ID NO:2), Mam004 (SEQ
ID NO:4) or Mam005 (SEQ ID NO:3) or an increase in levels of
BSGs such as Mam002 (SEQ ID NO:1) is associated with a cancer
which is regressing in stage or in remission.
15   Monitoring such patient for onset of metastasis is
periodic and preferably done on a quarterly basis. However,
this may be more or less frequent depending on the cancer, the
particular patient, and the stage of the cancer.

Assay Techniques

20   Assay techniques that can be used to determine levels
of gene expression, such as BSG of the present invention, in
a sample derived from a host are well-known to those of skill
in the art. Such assay methods include radioimmunoassays,
reverse transcriptase PCR (RT-PCR) assays,
25 immunohistochemistry assays, *in situ* hybridization assays,
competitive-binding assays, Western Blot analyses, ELISA
assays and proteomic approaches. Among these, ELISAs are
frequently preferred to diagnose a gene's expressed protein
in biological fluids.
30   An ELISA assay initially comprises preparing an
antibody, if not readily available from a commercial source,
specific to BSG, preferably a monoclonal antibody. In
addition a reporter antibody generally is prepared which binds
specifically to BSG. The reporter antibody is attached to a

detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to BSG is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time BSG binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to BSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to BSG. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to BSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of BSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to BSG attached to a solid support and labeled BSG and a sample derived from the host are passed over the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of BSG in the sample.

Nucleic acid methods may be used to detect BSG mRNA as a marker for breast cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population

- 12 -

in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR

5   reaction.   RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

10   Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene.   In this approach, a cDNA encoding the BSG gene is fixed to a substrate. The substrate may be of any suitable

15   type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the BSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

20   Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid.   Quantitation of the level of gene expression can be

25   done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

30   Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art.   Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels.

35   First, proteins are separated by size using an electric

current.   The current acts uniformly on all proteins, so
smaller proteins move farther on the gel than larger proteins.
The second dimension applies a current perpendicular to the
first and separates proteins not on the basis of size but on
5   the specific electric charge carried by each protein.   Since
no two proteins with different sequences are identical on the
basis of both size and charge, the result of a 2D separation
is a square gel in which each protein occupies a unique spot.
Analysis of the spots with chemical or antibody probes, or
10   subsequent protein microsequencing can reveal the relative
abundance of a given protein and the identity of the proteins
in the sample.

The above tests can be carried out on samples derived
from a variety of patients' cells, bodily fluids and/or tissue
15   extracts (homogenates or solubilized tissue) such as from
tissue biopsy and autopsy material.   Bodily fluids useful in
the present invention include blood, urine, saliva, or any
other bodily secretion or derivative thereof.   Blood can
include whole blood, plasma, serum, or any derivative of
20   blood.

In Vivo Antibody Use

Antibodies against BSGs can also be used *in vivo* in
patients with disease of the breast.   Specifically, antibodies
against a BSG can be injected into a patient suspected of
25   having a disease of the breast for diagnostic and/or
therapeutic purposes.   The use of antibodies for *in vivo*
diagnosis is well known in the art.   For example, antibody-
chelators labeled with Indium-111 have been described for use
in the radioimmunoscintographic imaging of carcinoembryonic
30   antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol.
1990 17:247-254).   In particular, these antibody-chelators
have been used in detecting tumors in patients suspected of
having recurrent colorectal cancer (Griffin et al. J. Clin.
Onc. 1991 9:631-640).   Antibodies with paramagnetic ions as

- 14 -

labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 1991 22:339-342). Antibodies directed against BSGs can be used in a similar manner. Labeled antibodies against a BSG can be

5   injected into patients suspected of having a disease of the breast such as breast cancer for the purpose of diagnosing or staging of the disease status of the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111,

10 Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadlinium (III) or Manganese (II) can used in magnetic resonance imaging

15 (MRI). Localization of the label within the breast or external to the breast permits determination of the spread of the disease. The amount of label within the breast also allows determination of the presence or absence of cancer in the breast.

20   For patients diagnosed with breast cancer, injection of an antibody against a BSG can also have a therapeutic benefit. The antibody may exert its therapeutic effect alone. Alternatively, the antibody is conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its

25 therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, *Cancer Research* 1986 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. *Cell* 1986

30 47:641-648). Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting toxicity to normal tissues (Goodwin and Meares Cancer Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-

131 and Rhenium-186 can also be used for labeling of antibodies against BSGs.

Antibodies which can be used in these *in vivo* methods include both polyclonal and monoclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

EXAMPLES

The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

Example 1

Identification of BSGs were carried out by a systematic analysis of data in the LIFESEQ database available from Incyte Pharmaceuticals, Palo Alto, CA, using the data mining Cancer Leads Automatic Search Package (CLASP) developed by diaDexus LLC, Santa Clara, CA.

The CLASP performs the following steps:

Selection of highly expressed organ specific genes based on the abundance level of the corresponding EST in the targeted organ versus all the other organs.

Analysis of the expression level of each highly expressed organ specific genes in normal, tumor tissue, disease tissue and tissue libraries associated with tumor or disease.

Selection of the candidates demonstrating component ESTs were exclusively or more frequently found in tumor libraries.

CLASP allows the identification of highly expressed organ and cancer specific genes useful in the diagnosis of breast cancer.

Table 1:   BSGs Sequences

SEQ ID NO:	LS Clone ID	LSA Gene ID
1	2740238 (Mam002)	242151
2	1730886 (Mam001)	238469
3	yl55b03 (Mam005)	348845
4	2613064 (Mam004)	27052
5	894184	221086
6	2299454	27681
7	2258254	248176
8	789767	156580
9	1213903	219737

The following example was carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

Example 2: Relative Quantitation of Gene Expression

Real-time quantitative PCR with fluorescent Taqman probes is a quantitative detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

- 17 -

Amplification of an endogenous control was used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used as this endogenous control. To calculate relative Quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System). To evaluate the tissue distribution, and the level of breast specific markers (BSM) Mam001 (SEQ ID NO:2), Mam002 (SEQ ID NO:1), Mam004 (SEQ ID NO:4) and Mam005 (SEQ ID NO:3) in normal and cancer tissue, total RNA was extracted from cancer and matched normal adjacent tissues (NAT) and from unmatched cancer and normal tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction carried out using primers and Taqman probes specific to each of Mam001 (SEQ ID NO:2), Mam002 (SEQ ID NO:1), Mam004 (SEQ ID NO:4) and Mam005 (SEQ ID NO:3) respectively. The results are obtained using the ABI PRISM 7700 Sequence Detector. The numbers are relative levels of expression of Mam001 (SEQ ID NO:2), Mam002 (SEQ ID NO:1), Mam004 (SEQ ID NO:4) and Mam005 (SEQ ID NO:3) compared to their respective calibrators.

Measurement of SEQ ID NO:2; Clone ID:1730886; Gene ID: 238469 (Mam001)

The numbers depicted in Table 2 are relative levels of expression in 12 normal tissues of Mam001 (SEQ ID NO:2) compared to testis (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue from different individuals.

Table 2: Relative levels of Mam001 (SEQ ID NO:2) Expression
in Pooled Samples

Tissue	NORMAL
Brain	0
Heart	0
Kidney	0
Liver	0
Lung	0
Mammary	6
Prostate	0
Muscle	0
Small Intestine	0
Testis	1
Thymus	0
Uterus	0

The relative levels of expression in Table 2 show that
Mam001 (SEQ ID NO:2) mRNA expression is detected in the pool
of normal mammary and in testis but not in the other 10 normal
tissue pools analyzed. These results demonstrate that Mam001
(SEQ ID NO:2) mRNA expression is highly specific for mammary
tissue and is also found in testis. Expression in a male
specific tissue is not relevant in detecting cancer in female
specific tissues

The tissues shown in Table 2 are pooled samples from
different individuals. The tissues shown in Table 3 were
obtained from individuals and are not pooled. Hence the
values for mRNA expression levels shown in Table 2 cannot be
directly compared to the values shown in Table 3.

The numbers depicted in Table 3 are relative levels of
expression of Mam001 (SEQ ID NO:2) compared to testis
(calibrator), in 24 pairs of matching samples. Each matching
pair contains the cancer sample for a particular tissue and
the normal adjacent tissue (NAT) sample for that same tissue
from the same individual.

Table 3:   Relative levels of Mam001 (SEQ ID NO:2) Expression
in Individual Samples

Sample ID	Tissue	Cancer	Matching Normal
Mam 47XP	Mammary Gland	0	0
Mam A06X	Mammary Gland	23	1
Mam B011X	Mammary Gland	0	5
Mam 603X/C034	Mammary Gland	0	2.10
Mam 162X	Mammary Gland	1.96	0.15
Mam 42DN	Mammary Gland	0.38	1.27
Mam S079	Mammary Gland	0.34	0.36
Mam S123	Mammary Gland	0.03	0.87
Mam S516	Mammary Gland	0.43	0.53
Mam S699	Mammary Gland	0.40	0.66
Mam S997	Mammary Gland	0.41	0.51
Sto AC44	Stomach	0	0
TST 39X	Testis	0	0
Cln SG45	Colon	0	0
Cln TX01	Colon	0	0
Cvx NK23	Cervix	0	0
Cvx NK24	Cervix	0	0
Endo 3AX	Endometrium	0	0
Endo 4XA	Endometrium	0	0
Endo 5XA	Endometrium	0	0
Kid 11XD	Kidney	0	0
Kid 5XD	Kidney	0	0
Lng C20X	Lung	0	0
Lng SQ56	Lung	0	0

Among 48 samples in Table 3 representing 8 different
tissues expression is seen only in mammary tissues. These
results confirm the tissue specificity results obtained with

- 20 -

normal samples shown in Table 2. Table 2 and Table 3 represent a combined total of 60 samples in 16 human tissue types. Thirty-six samples representing 14 different tissue types excluding breast and testis had no detected Mam001 (SEQ
5 ID NO:2) mRNA (Table 2 and 3). Other than breast tissue, Mam001 (SEQ ID NO:2) is detected only in one other tissue type (Testis) and then only in the pooled tissue sample (Table 2) but not in the matched testis cancer samples (Table 3).

       Comparisons of the level of mRNA expression in breast
10 cancer samples and the normal adjacent tissue from the same individuals are shown in Table 3. Mam001 (SEQ ID NO:2) is expressed at higher levels in 2 of 11 breast cancer tissues (Mam A06X and Mam 162X) compared with the corresponding normal adjacent tissue. The level of Mam001 (SEQ ID NO:2) expression
15 is lower in breast cancer compared to normal adjacent tissue in four matched samples (Mam B011X, Mam 603X/CO34, Mam 42DN and Mam S123). No expression was detected in one set of matched samples (Mam 47XP). Equivalent levels or very similar levels of expression were detected in four other matched
20 samples (Mam S079, Mam S516, Mam S699 and Mam S997). However increasing cancer mass might in these cases result in an overall increase in the total amount of expression.

       The high level of tissue specificity and increased or equivalent expression in 6 of 11 individuals is demonstrative
25 of Mam001 (SEQ ID NO:2) being a diagnostic marker for detection of mammary cancer cells using mRNA.

Measurement of SEQ ID NO:1; Clone ID: 2740238; Gene ID 242151 (Mam002)

       The numbers depicted in Table 5 are relative levels of
30 expression in 12 normal tissues of Mam002 (SEQ ID NO:1) compared to Thymus (calibrator). These RNA samples were obtained commercially and were generated by pooling samples from a particular tissue from different individuals.

Table 4: Relative levels of Mam002 (SEQ ID NO:1) Expression in Pooled Samples

Tissue	NORMAL
Brain	0.03
Heart	0.01
Kidney	0
Liver	0
Lung	0.06
Mammary	289.01
Muscle	0
Prostate	0.31
Small Int.	0
Testis	0.08
Thymus	1.00
Uterus	0

The relative levels of expression in Table 4 show that Mam002 (SEQ ID NO:1) mRNA expression is detected at a high level in the pool of normal mammary but at very low levels in the other 11 normal tissue pools analyzed. These results demonstrate that Mam002 (SEQ ID NO:1) mRNA expression is highly specific for mammary tissue.

The tissues shown in Table 4 are pooled samples from different individuals. The tissues shown in Table 5 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 4 cannot be directly compared to the values shown in Table 5.

The numbers depicted in Table 5 are relative levels of expression of Mam002 (SEQ ID NO:1) compared to thymus (calibrator) in 27 pairs of matching samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue (NAT) sample for that same tissue from the same individual. In addition 2 unmatched mammary samples from normal tissues and one unmatched ovarian cancer and one normal (non-cancerous) ovary were also tested.

Table 5: Relative levels of Mam002 (SEQ ID NO:1) Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching	Normal
Mam 12X	Mammary Gland	7.2	69	
Mam 42DN	Mammary Gland	1051	2075	
Mam 59X	Mammary Gland	7.0	15.5	
Mam A06X	Mammary Gland	1655	1781	
Mam B011X	Mammary Gland	32.1	2311	
Mam S127	Mammary Gland	1.73	0	
Mam S516	Mammary Gland	9.72	69.95	
Mam S699	Mammary Gland	83.46	75.65	
Mam S854	Mammary Gland	133.23	836.56	
Mam S967	Mammary Gland	59.77	188.28	
Mam S997	Mammary Gland	94.14	73.64	
Mam 162X	Mammary Gland	674.0	31.1	
Mam C012	Mammary Gland	N/A	N/A	11379.3
Mam C034	Mammary Gland	N/A	N/A	3502.6
Mam S079	Mammary Gland	11772.5	903.5	
Mam S123	Mammary Gland	3.4	170.5	
Ovr 103X	Ovary	0	0	
Ovr 1118	Ovary	0.13	N/A	

Ovr 35GA	Ovary	N/A	N/A	0.13
Utr 23XU	Uterus	5.6	0	
Utr 135XO	Uterus	0	0	
Cvx NK24	Cervix	0.9	1.4	
End 4XA	Endometrium	32.2	0	
Cln AS43	Colon	2.3	0	
Cln AS45	Colon	0	0	
Cln RC01	Colon	0.2	0	
Lng AC90	Lung	0	2.0	
Lng LC109	Lung	0	0.6	
Lng SC32	Lung	0.8	0	
Sto AC93	Stomach	0	0	
Tst 39X	Testis	1.97	0	

Among 58 samples in Table 5 representing 9 different tissues, the highest expression is seen in mammary tissues. Amongst the non-breast tissues which show expression, only one sample (End 4XA) has expression comparable to that seen in the majority of the breast samples tested. This sample is endometrial tissue, which is a female specific tissue. These results confirm the tissue specificity results obtained with normal samples shown in Table 4. Table 4 and Table 5 represent a combined total of 70 samples in 17 human tissue types. Twenty-two samples representing 11 different tissue types excluding breast had no detected Mam002 (SEQ ID NO:1) mRNA (Table 4 and Table 5).

Comparisons of the level of mRNA expression in breast cancer samples and the normal adjacent tissue from the same individuals are shown in Table 5. Mam002 (SEQ ID NO:1) is expressed at higher levels in 3 of 13 matched breast cancer tissues (Samples Mam S127, Mam 162X and Mam S079) compared with the corresponding normal adjacent tissue. The level of Mam002 (SEQ ID NO:1) expression is lower in breast cancer

compared to normal adjacent tissue in eight individuals (Mam
12X, Mam 42DN, Mam 59X, Mam B011X, Mam S516, Mam S854, Mam
S967, and Mam S123). Equivalent levels or very similar levels
of expression were detected in three other matched samples
5 (Samples Mam A06X, Mam S699 and Mam S997).

The high level of tissue specificity is demonstrative
of Mam002 (SEQ ID NO:1) being a diagnostic marker for
detection of mammary cancer cells using mRNA. Breast tissue
is the only significant source of this gene's expression so
10 far detected. Eight of 13 matched samples have lower levels
of expression in cancer than normal adjacent tissue. Thus,
decreased expression of this gene appears to be diagnostic of
cancer presence.

Measurement of SEQ ID NO:4; Clone ID: 2613064; Gene ID: 27052
15 **(Mam004)**

The numbers depicted in Table 6 are relative levels of
expression in 12 normal tissues of Mam004 (SEQ ID NO:4)
compared to mammary (calibrator). These RNA samples were
obtained commercially and were generated by pooling samples
20 from a particular tissue from different individuals.

**Table 6:   Relative levels of Mam004 (SEQ ID NO:4) Expression
in Pooled Samples**

Tissue	NORMAL
Brain	0.059
Heart	0.131
Kidney	0.018
Liver	0
Lung	0.478
Mammary	1.000
Prostate	0.459
Muscle	0.003
Small Intestine	0.048
Testis	0.130
Thymus	0.030
Uterus	0.071

The relative levels of expression in Table 6 show that Mam004
(SEQ ID NO:4) mRNA expression is detected in the pool of

- 25 -

normal mammary and also in other tissues including lung,
prostate, testis and heart. These results demonstrate that
although more highly expressed in normal breast tissue
Mam004(SEQ ID NO:4) mRNA expression is not specific for
5   mammary gland.

      The tissues shown in Table 6 are pooled samples from
different individuals. The tissues shown in Table 7 were
obtained from individuals and are not pooled. Hence the
values for mRNA expression levels shown in Table 6 cannot be
10 directly compared to the values shown in Table 7.

      The numbers depicted in Table 7 are relative levels of
expression of Mam004 (SEQ ID NO:4) compared to mammary
(calibrator), in 23 pairs of matching samples. Each matching
pair contains the cancer sample for a particular tissue and
15 the normal adjacent tissue (NAT) sample for that same tissue
from the same individual.

**Table 7: Relative levels of Mam004 (SEQ ID NO:4) Expression
in Individual Samples**

Sample ID	Tissue	Cancer	Matching
Mam 12B	Mammary Gland	0	0
Mam 12X	Mammary Gland	13.454	0
Mam 603X	Mammary Gland	30.484	0
Mam 59X	Mammary Gland	1.306	0
Mam 162X	Mammary Gland	0.71	0.04
Mam 42DN	Mammary Gland	0.25	2.17
Mam S079	Mammary Gland	42.18	0.47
Mam S123	Mammary Gland	0.01	0
Mam S516	Mammary Gland	1.17	0.41
Mam S699	Mammary Gland	0.11	0.55
Mam S997	Mammary Gland	10.43	1.29
Sto AC44	Stomach	0.61	0

Cln SG45	Colon	0.04	0
Cln TX01	Colon	0	0
Cvx NK23	Cervix	0	0
Cvx NK24	Cervix	0	0
Endo 3AX	Endometrium	0	0
Endo 4XA	Endometrium	0	0
Endo 5XA	Endometrium	0	2.73
Kid 11XD	Kidney	0	0
Kid 5XD	Kidney	0	2.63
Lng C20X	Lung	0	0
Lng SQ56	Lung	10.37	0

Among 46 samples in Table 7 representing 7 different tissues expression is highest in breast tissues particularly cancers. Expression comparable to that seen in breast samples is also seen in 1 of 4 lung samples (Sample 23), 1 of 4 kidney samples (Sample 21) and 1 of 6 endometrial samples (Sample 19). Table 6 and Table 7 represent a combined total of 58 samples in 16 human tissue types. Twenty samples representing 7 different tissue types excluding breast had no detected Mam004 (SEQ ID NO:4) mRNA (Table 6 and Table 7).

Comparisons of the level of mRNA expression in breast cancer samples and the normal adjacent tissue from the same individuals are shown in Table 7. Mam004 (SEQ ID NO:4) is expressed at higher levels in 8 of 11 breast cancer tissues (Mam 12X, Mam 603X, Mam 59X, Mam 162X, Mam S079, Mam S123, Mam S516 and Mam S997) compared with the corresponding normal adjacent tissue. The level of Mam004 (SEQ ID NO:4) expression is lower in breast cancer compared to normal adjacent tissue in two matched samples (Mam 42DN and Mam S699). No expression was detected in one matched sample (Mam 12B).

Elevated expression in the majority of matched cancer samples compared to normal adjacent tissue is indicative of

Mam004 (SEQ ID NO:4) being a diagnostic marker for detection
of mammary cancer cells using mRNA.

**Measurement of SEQ ID NO:3; Clone ID:y155b03; Gene ID: 348845
(Mam005)**

5   The numbers depicted in Table 8 are relative levels of
expression in 12 normal tissues of Mam005 (SEQ ID NO:3)
compared to testis (calibrator). These RNA samples were
obtained commercially and were generated by pooling samples
from a particular tissue from different individuals.

10 **Table 8:   Relative levels of Mam005 (SEQ ID NO:3) Expression
in Pooled Samples**

Tissue	NORMAL
Brain	0
Heart	0.0002
Kidney	0.0001
Liver	0
Lung	0
Mammary	5.4076
Muscle	0
Prostate	0
Small Intestine	0
Testis	1
Thymus	0
Uterus	0

25 The relative levels of expression in Table 8 show that Mam005
(SEQ ID NO:3) mRNA expression is detected in the pool of
normal mammary and in testis but is not present at significant
levels in the other 10 normal tissue pools analyzed. These
results demonstrate that Mam005 (SEQ ID NO:3) mRNA expression
30 is highly specific for mammary tissue and is also found in
testis. Expression in a male specific tissue is not relevant
in detecting cancer in female specific tissues.

        The tissues shown in Table 8 are pooled samples from
different individuals. The tissues shown in Table 9 were
35 obtained from individuals and are not pooled. Hence the
values for mRNA expression levels shown in Table 8 cannot be
directly compared to the values shown in Table 9.

The numbers depicted in Table 9 are relative levels of expression of Mam005 (SEQ ID NO:3) compared to testis (calibrator), in 46 pairs of matching samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent tissue sample for that same tissue from the same individual. In addition 2 unmatched mammary samples from normal tissues and one unmatched ovarian cancer and one normal (non-cancerous) ovary were also tested.

Table 9: Relative levels of Mam005 (SEQ ID NO:3) Expression in Individual Samples

Sample ID	Tissue	Cancer	Matching	Normal
Mam 12X	Mammary Gland	0.33	0.71	
Mam 42DN	Mammary Gland	0.22	0.63	
Mam 59X	Mammary Gland	0.03	0.23	
Mam A06X	Mammary Gland	70.77	0.56	
Mam B011X	Mammary Gland	0.03	1.52	
Mam 162X	Mammary Gland	0.43	0.09	
Mam C012	Mammary Gland	N/A	N/A	1.6
Mam C034	Mammary Gland	N/A	N/A	2.9
Mam S079	Mammary Gland	0.22	0.13	
Mam S123	Mammary Gland	0.01	0.23	
Mam S127	Mammary Gland	0	0.28	
Mam S516	Mammary Gland	0.15	0.05	

Mam S699	Mammary Gland	0.21	0.42	
Mam S854	Mammary Gland	1.12	0.54	
Mam S967	Mammary Gland	30.61	0.54	
Mam S997	Mammary Gland	0.40	0.22	
Mam 14DN	Mammary Gland	0.07	0	
Mam 699F	Mammary Gland	0.01	0.09	
Mam S621	Mammary Gland	1.82	0	
Mam S918	Mammary Gland	6.89	1.06	
Cln CM67	Colon	0	0	
Cln DC19	Colon	0	0	
Cln AS43	Colon	0	0	
Cln AS45	Colon	0	0	
Cln RC01	Colon	0.0012	0.0003	
Lng AC90	Lung	0	0	
Lng LC109	Lung	0	0	
Lng SQ32	Lung	0	0	
Lng SQ43	Lung	0	0	
Ovr 103X	Ovary	0	0	
Ovr 1118	Ovary	0	N/A	
Ovr A084	Ovary	0	0	
Ovr G021	Ovary	0	0	
Ovr 35GA	Ovary	N/A	N/A	0
Cvx NK23	Cervix	0	0	
Cvx NK24	Cervix	0	0	
Endo 3AX	Endometrium	0	0	

Endo 4XA	Endometrium	0	0	
Sto 758S	Stomach	0	0	
Sto AC44	Stomach	0	0	
Sto AC93	Stomach	0	0	
Tst 39X	Testis	0.01	0.01	
Utr 85XU	Uterus	0	0	
Utr 135XO	Uterus	0	0	
Utr 23XU	Uterus	0	0	
Kid 124D	Kidney	0	0	
Lvr 15XA	Liver	0	0	
Pan CO44	Pancreas	0	0	
Skn 448S	Skin	0	0	
SmInt 21XA	Small Intestines	0	0	

Among 96 samples in Table 9 representing 14 different tissues
significant expression is seen only in breast tissues. These
results confirm the tissue specificity results obtained with
normal samples shown in Table 8.   Table 8 and Table 9
represent a combined total of 108 samples in 18 human tissue
types. Sixty-seven samples representing 16 different tissue
types excluding breast and testis had either no or very low
levels of detected Mam005 (SEQ ID NO:3) mRNA (Table 8 and
Table 9).

Comparisons of the level of mRNA expression in breast
cancer samples and the normal adjacent tissue from the same
individuals are shown in Table 9.   Mam005 (SEQ ID NO:3) is
expressed at higher levels in 10 of 18 cancer and normal
adjacent tissue samples (Mam A06X, Mam 162X, Mam S079, Mam
S516, Mam S854, Mam S967, Mam S997, Mam 14DN, Mam S621, and
Mam S918) compared with the corresponding normal adjacent
tissue. The level of Mam005 (SEQ ID NO:3) expression is lower
in breast cancer compared to normal adjacent tissue in eight

cancer and normal adjacent tissue samples (Mam 12X, Mam 42DN, Mam 59X, Mam B011X, Mam S123, Mam S127, Mam S699 and Mam 699F). No expression was detected in two matching samples.

The high level of tissue specificity and overexpression in 10 of 18 matched cancer and normal adjacent tissue samples is indicative of Mam005 (SEQ ID NO:3) being a diagnostic marker for detection of mammary cancer cells using mRNA.

What is claimed is:

1. A method for diagnosing the presence of breast cancer in a patient comprising:

(a) measuring levels of BSG in cells, tissues or bodily

5 fluids in said patient; and

(b) comparing measured levels of BSG with levels of BSG in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of BSG in the patient versus normal human control is associated with the

10 presence of breast cancer.

2. A method of diagnosing metastatic breast cancer in a patient having breast cancer comprising:

(a) identifying a patient having breast cancer that is not known to have metastasized;

15 (b) measuring levels of BSG in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the measured BSG levels with levels of BSG in cells, tissue, or bodily fluid type of a normal human control, wherein a change in measured BSG levels in the

20 patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging breast cancer in a patient comprising:

(a) identifying a patient having breast cancer;

25 (b) measuring levels of BSG in a sample of cells, tissues, or bodily fluid from said patient for BSG; and

(c) comparing measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control sample, wherein a change in measured BSG levels in said

30 patient versus the normal human control is associated with a cancer which is progressing or regressing or in remission.

4. A method of monitoring breast cancer in a patient having breast cancer for the onset of metastasis comprising:

(a) identifying a patient having breast cancer that is not known to have metastasized;

5   (b) periodically measuring BSG levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control, wherein a change in BSG levels in the patient versus

10 the normal human control is associated with a cancer which has metastasized.

5. A method of monitoring the change in stage of breast cancer in a patient having breast cancer comprising:

(a) identifying a patient having breast cancer;

15   (b) periodically measuring BSG levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the measured BSG levels with levels of BSG in cells, tissues, or bodily fluid type of a normal human control, wherein a change in measured BSG levels in the

20 patient versus the normal human control is associated with a cancer which is progressing in stage, which is regressing in stage, or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the change associated with the presence, metastasis or progression

25 of breast cancer in said patient is an increase in measured BSG levels in the patient and the BSG comprises Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3).

7. The method of claim 1, 2, 3, 4 or 5 wherein the change associated with the presence, metastasis or progression

30 of breast cancer in said patient is a decrease in measured BSG levels in the patient and the BSG comprises Mam002 (SEQ ID NO:1).

8.   The method of claim 3 or 5 wherein the change associated with the regression or remission of breast cancer in said patient is a decrease in measured BSG levels in the patient and the BSG comprises Mam001 (SEQ ID NO:2), Mam004

5   (SEQ ID NO:4) or Mam005 (SEQ ID NO:3).

9.   The method of claim 3 or 5 wherein the change associated with the regression or remission of breast cancer in said patient is an increase in measured BSG levels in the patient and the BSG comprises Mam002 (SEQ ID NO:1).

10   10.   An antibody against a BSG wherein said BSG comprises Mam001 (SEQ ID NO:2), Mam004 (SEQ ID NO:4) or Mam005 (SEQ ID NO:3).

11.   A method of imaging breast cancer in a patient comprising administering to the patient an antibody of claim

15   10.

12.   The method of claim 11 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

13.   A method of treating breast cancer in a patient comprising administering to the patient an antibody of claim

20   10.

14.   The method of claim 13 wherein the antibody is conjugated to a cytotoxic agent.

DEY-0040

PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification [6]: **C12Q 1/68, C12P 19/34, C07H 21/04, A61K 16/00, G01N 33/53**	**A1**

(11) International Publication Number: WO 00/08210

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/US99/16811

(22) International Filing Date: 22 July 1999 (22.07.99)

(30) Priority Data:
60/095,232   4 August 1998 (04.08.98)   US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application
US   60/095,232 (CIP)
Filed on   4 August 1998 (04.08.98)

(71) Applicant *(for all designated States except US)*: DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). CAFFERKEY, Robert [IE/US]; Apartment 218, 350 Elan Village Lane, San Jose, CA 95134 (US).

(74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING BREAST CANCER

(57) Abstract

The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating breast cancer.

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Breast Cancer

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on ___July 22, 1999___ as United States Application No. or PCT International

Application Number ___PCT/US99/16811___

and was amended on ___

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)	(Country)	(Day/Month/Year Filed)	☐
(Number)	(Country)	(Day/Month/Year Filed)	☐
(Number)	(Country)	(Day/Month/Year Filed)	☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/095,232	August 4, 1998
(Application Serial No.)	(Filing Date)

(Application Serial No.)	(Filing Date)

(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)* ,

26259

PATENT TRADEMARK OFFICE

Send Correspondence to: Jane Massey Licata or Kathleen A. Tyrrell

Licata & Tyrrell P.C.

66 E. Main Street

Marlton, New Jersey 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor **Yongming Sun**	
Sole or first inventor's signature	Date 7-20-2001
Residence **San Jose, California**	CA
Citizenship **China**	
Post Office Address **869 S. Winchester Boulevard, Apartment 260**	
San Jose, California 95128	

Full name of second inventor, if any **Herve Recipon**	
Second inventor's signature	Date 7-23-01
Residence **San Francisco, California**	CA
Citizenship **France**	
Post Office Address **85 Fortuna Avenue**	
San Francisco, California 94115	

Form PTO-SB-01 (6-95) (Modified)   Patent and Trademark Office-U.S. DEPARTMENT OF COMMERCE

3-00

Full name of third inventor, if any
Robert Cafferkey

Third inventor's signature

7-18-01

Date

Residence
San Jose, California

CA

Citizenship
Ireland

Post Office Address
350 Elan Village Lane, Apartment 218

San Jose, California 95134

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address

Form PTO-SB-01 (6-95) (Modified)   Patent and Trademark Office-U.S. DEPARTMENT OF COMMERCE

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27 (c)) - SMALL BUSINESS CONCERN	Docket No. DEX-0154

Serial No.	Filing Date	Patent No.	Issue Date
Not Yet Assigned	Herewith		

Applicant/ SUN, Yongming et al.
Patentee:

Invention: A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Breast Cancer

I hereby declare that I am:

☐ the owner of the small business concern identified below:

☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: diaDexus, Inc.
ADDRESS OF CONCERN: 3303 Octavius Drive, Santa Clara, California 95054

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:

☒ the specification filed herewith with title as listed above.

☐ the application identified above.

☐ the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

☒ no such person, concern or organization exists.
☐ each such person, concern or organization is listed below.

FULL NAME
ADDRESS _____

☐ Individual   ☐ Small Business Concern   ☐ Nonprofit Organization

FULL NAME
ADDRESS _____

☐ Individual   ☐ Small Business Concern   ☐ Nonprofit Organization

FULL NAME
ADDRESS _____

☐ Individual   ☐ Small Business Concern   ☐ Nonprofit Organization

FULL NAME
ADDRESS _____

☐ Individual   ☐ Small Business Concern   ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Mohan Iyer

TITLE OF PERSON SIGNING
OTHER THAN OWNER: Vice President, Business Development

ADDRESS OF PERSON SIGNING: diaDexus, Inc.
                               3303 Octavius Drive
                               Santa Clara, California 95054

SIGNATURE: _____Mohan Iyer_____   DATE: __1/29/01__